Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by Inthepezon Sep 28, 2021 10:55am
148 Views
Post# 33930375

Anytime RATbar99 says he’s bullish remember this

Anytime RATbar99 says he’s bullish remember this 1- Today's report was the final nail in the coffin. Ever after the stock dropped 65% overnight, only 1 out of 40 insiders bought the dip, and he only bought around 10K shares at a price of $1.03 which is laughable considering he is the CEO..

2-
Whether this company recovers or not, it's going to be a LOOONG two months until they release the report.. The odds of this going below $1 are almost guaranteed. How do you possibly expect this to stay above $1 without any news for 2 months? And the news could eventually end up being so bad that it will tank this stock further. This is going to be a nightmare for share holders whether you like it or not.

3- 
There's a good chance the report will be unfavourable, and there's a strong possibility that they will entirely cancel the project. But we still have to wait 2 months just to hear that. A slow death -- if you will. Good luck.

4-
I found this stock (and this thread) after it crashed. Are you proud that you were here longer and held through the 70% drop? That's a weird flex but nothing I would brag about.

5-
I'm a random retail investor who stumbled upon this stock after it crashed, and I bought twice as many stocks as their entire insiders did. And all I bought was play moneys worth, I don't consider this as an actual investment.
<< Previous
Bullboard Posts
Next >>